(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno- oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of $1,100,000.
- 0 Comments
- FY2021